Figure 1.

Flow chart of the AIO KRK 0110 Trial/ML22011 Trial. Patients are randomized to either receive single-agent chemotherapy (Cape-Bev) and escalation to CAPIRI-Bev at progressive disease or combination chemotherapy (CAPIRI-Bev) with an de-escalation option to Cape-Bev and subsequent re-escalation if necessary.

Giessen et al. BMC Cancer 2011 11:367   doi:10.1186/1471-2407-11-367
Download authors' original image